Sage Journals: Discover world-class research

Open access

Research article

First published 2016-9

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S Freedman [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2018-1

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Eva Havrdová, Douglas L Arnold, Amit Bar-Or [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2018

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis

Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2018

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

Lara Diem, Krassen Nedeltchev, Timo Kahles [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2019-5

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b

Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2017-2

NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs

Maria Pia Sormani, Paolo A Muraro, Riccardo Saccardi [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-11

Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status,including brain volume loss

Jarmila Szilasiová, Pavol Mikula, Jaroslav Rosenberger [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-7

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

Gavin Giovannoni, Barry A Singer, Delphine Issard [...]

Multiple Sclerosis Journal

Retricted access

Editorial

First published 2016-1

Are we in need of NEDA?

Mark S Freedman

Multiple Sclerosis Journal

Retricted access

Research article

First published 2025-6

Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study

Nabil K El Ayoubi, Mark N Bal, Nicole Metri [...]

Multiple Sclerosis Journal

Search results